COMMUNIQUÉS West-GlobeNewswire

-
Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema
16/01/2025 -
Avicanna Announces Scientific and Medical Affairs Collaboration with Vectura Fertin Pharma
16/01/2025 -
The Joint Corp. Reports 2024 Operating Metrics
16/01/2025 -
Avacta Announces Positive New Data from the AVA6000 Phase 1 trial Demonstrating Clinically Meaningful Tumor Shrinkage in Patients with Salivary Gland Cancers
16/01/2025 -
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
16/01/2025 -
Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale
16/01/2025 -
Micron Biomedical Extends Series A Financing to 33+ Million to Accelerate Commercialization of Needle-Free Therapeutics and Vaccines
16/01/2025 -
Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial
16/01/2025 -
KFSHRC Launches Precision Medicine Services in Family Medicine Clinics to Enhance Access to the Latest Genetic Tests
16/01/2025 -
Actimed Therapeutics appoints Dr Fabio Dorigotti as Chief Medical Officer to drive further pipeline development for cancer cachexia and other muscle wasting disorders
16/01/2025 -
Phonak expands award-winning Infinio portfolio with two new custom hearing aids
16/01/2025 -
Santhera Receives Positive NICE Final Guidance for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
16/01/2025 -
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
14/01/2025 -
Rapid Micro Biosystems Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenue
14/01/2025 -
Enzo Biochem Receives Notice of Non-Compliance with New York Stock Exchange Listing Rules
14/01/2025 -
Vericel Announces Preliminary 2024 Financial Results, 2025 Financial Guidance and Increased Mid-Term Profitability Targets
14/01/2025 -
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
14/01/2025 -
Evaxion announces completion of ADS ratio change
14/01/2025 -
OP Solutions Appoints Michael Kallish as Chief Executive Officer
14/01/2025
Pages